急性皮膚エリテマト-デス(ACLE):治療薬市場2018(世界市場規模、APIメーカー、市販薬、フェーズ3治験薬)

【英語タイトル】Acute Cutaneous Lupus Erythematosus (ACLE)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018

DelveInsightが出版した調査資料(DIIR2016178)・商品コード:DIIR2016178
・発行会社(調査会社):DelveInsight
・発行日:2018年11月
・ページ数:約100
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
※当調査レポートでは、急性皮膚エリテマト-デス(ACLE)治療薬の世界市場動向について調査・分析し、以下の構成でお届けいたします。

・急性皮膚エリテマト-デス(ACLE):適応症(疾患)の概要
・市販医薬品の状況
・世界のAPI(医薬品原薬)メーカー分析
・地域別APIメーカー状況(アメリカ、ヨーロッパ、中国など)
・急性皮膚エリテマト-デス(ACLE)のフェーズ3治験薬の状況
・急性皮膚エリテマト-デス(ACLE)治療薬の市場規模(販売予測)
・急性皮膚エリテマト-デス(ACLE)の市販医薬品分析
 (医薬品名、説明、APIメーカー、承認状況、特許など)
・急性皮膚エリテマト-デス(ACLE)のフェーズ3治験薬分析
・開発中止中の急性皮膚エリテマト-デス(ACLE)治療薬剤
【レポートの概要】

SUMMARY
DelveInsight’s Report, “Acute Cutaneous Lupus Erythematosus (ACLE)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Acute Cutaneous Lupus Erythematosus (ACLE) Report is to understand the market and pipeline status of the drugs around the Acute Cutaneous Lupus Erythematosus (ACLE) to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2020. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Acute Cutaneous Lupus Erythematosus (ACLE). While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


SCOPE:
• A snapshot of the global Market and Phase III therapeutics scenario for Acute Cutaneous Lupus Erythematosus (ACLE).
• A review of the marketed products under prescription for Acute Cutaneous Lupus Erythematosus (ACLE), regulatory information and marketing status.
• Coverage of global patent coverage and detailed commentaries on the US patent challenges.
• Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
• Product profiles for marketed products for Acute Cutaneous Lupus Erythematosus (ACLE) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
• Coverage of API Manufacturers for Acute Cutaneous Lupus Erythematosus (ACLE) drugs in the United States, Europe and Asian Regions with location details.
• Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Acute Cutaneous Lupus Erythematosus (ACLE) drugs.
• Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Acute Cutaneous Lupus Erythematosus (ACLE) drugs.
• Coverage of Acute Cutaneous Lupus Erythematosus (ACLE) Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
• Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
• Key discontinued Marketed products.
• Global Sales Figure to 2020.


【レポートの目次】

1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2020
6. Marketed Drugs for Acute Cutaneous Lupus Erythematosus (ACLE)
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Acute Cutaneous Lupus Erythematosus (ACLE)
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Acute Cutaneous Lupus Erythematosus (ACLE)
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer

List of Tables
• Acute Cutaneous Lupus Erythematosus (ACLE) Therapeutic Market, US, Marketed Drugs by Application Type, 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Therapeutic Market, US, Marketed Drugs by Marketing Status, 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Therapeutic Market, US, (Year), 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Marketed Drugs, API Manufacturers by US DMF Status, 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Marketed Drugs, US DMF Status Drug Specific (Number), 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Drugs, API Manufacturers, Europe by Country, 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Drugs, API Manufacturers, India by State, 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Drugs, API Manufacturers, China by Province, 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Drugs, API Manufacturers by Geography 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Therapeutic Market, Global Sales-2020 (in million USD)
• API Manufacturers for Drug, 2018
• Phase III Drugs for Acute Cutaneous Lupus Erythematosus (ACLE), 2018
• Discontinued Drugs for Acute Cutaneous Lupus Erythematosus (ACLE), 2018


List of Figures
• Acute Cutaneous Lupus Erythematosus (ACLE) Therapeutic Market, US, Marketed Drugs by Application Type (%), 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Therapeutic Market, US, (Year), 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Marketed Drugs, API Manufacturers by US DMF Status (%), 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Marketed Drugs, US DMF Status Drug Specific (Number), 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Drugs, API Manufacturers, Europe by Country, 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Drugs, API Manufacturers, India by State, 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Drugs, API Manufacturers, China by Province, 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Drugs, API Manufacturers by Geography 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2018
• Acute Cutaneous Lupus Erythematosus (ACLE) Therapeutic Market, Global Sales 2020 (in million USD)
• Drug, Patent/Exclusivity Expiry (Year), 2018


【レポートのキーワード】

急性皮膚エリテマト-デス(ACLE)、薬剤、治療薬、市場規模、販売量、医薬品有効成分(API)メーカー、治験、上市品(市販薬)

★調査レポート[急性皮膚エリテマト-デス(ACLE):治療薬市場2018(世界市場規模、APIメーカー、市販薬、フェーズ3治験薬)] (コード:DIIR2016178)販売に関する免責事項を必ずご確認ください。
★調査レポート[急性皮膚エリテマト-デス(ACLE):治療薬市場2018(世界市場規模、APIメーカー、市販薬、フェーズ3治験薬)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆